Skip to main content
Signal8

Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

NASDAQ:UNCY

Unicycive Therapeutics, Inc. (UNCY) dilution facts from SEC filings

Snapshot as of Sep 30, 2026, built from 39 SEC filings.

Shelf registration
S-3 filed Jun 5, 2026, effective Jun 15, 2026
Source: S-3 filed Jun 5, 2026
At-the-market (ATM) program
Yes, sales agreement dated Nov 13, 2024
Source: 10-Q filed Nov 16, 2026
Warrants outstanding
3 warrant series recorded as outstanding
Most recent offering
None recorded in the filings reviewed

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro